Circulating Endothelial Progenitor Cells and Their Relation to Thrombosis in Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia
Open Access
- 26 May 2021
- journal article
- research article
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 38 (2) , 319-326
Abstract
Thrombosis is a leading cause of morbidity and mortality in paroxysmal nocturnal hemoglobinuria (PNH). Multiple factors are responsible for the thrombotic tendency in these patients. Endothelial progenitorcells (EPCs) originate from primitive hematopoietic stem cells. The EPC count is considered indicative of potential damage and restoration capacity in vascular disease; lower EPC counts are deemed as a risk factor in cardiovascular diseases. We aimed to investigate the count of circulating EPCs in PNH and aplastic anemia (AA) patients receiving eculizumab treatment or not receiving treatment and their relationship with thrombosis. Seventeen PNH patients, 18 AA patients, and 10 healthy volunteers were included in the study. The CD309, CD133, and CD34 antibodies were used to determine counts of circulating EPCs using flowcytometry. EPC levels were compared between the PNH, AA, and healthy control groups. Kolmogorov–Smirnov test. ANOVA, Kruskal–Wallis, and Mann–Whitney U testswereperformedto analyze the quantitative data, while χ2 testing was performed to analyze the qualitative data. Therewasnosignificantdifference in EPC levelsbetweenpatientswithandwithout a history of thrombosis (P > 0.05). Further, therewasnosignificantdifference in thelevels of EPCsbetweenthe AA and PNH groups (P > 0.05). However, there was a significant positive correlation between levels of EPCs and lactate dehydrogenase (LDH) in multivariate analysis (P < 0.05). The study findings suggest that hemolysis promotes vascular endothelial and new blood vessel formation. Increased EPCs in PNH may indirectly indicatevascular endothelial damage in PNH.Keywords
This publication has 30 references indexed in Scilit:
- Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulationExperimental Hematology & Oncology, 2012
- Thrombophilic screening in patients with paroxysmal nocturnal haemoglobinuria: a pilot studyBritish Journal of Haematology, 2010
- Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporineHaematologica, 2010
- Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2010
- Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumabHaematologica, 2010
- Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology, and managementAmerican Journal of Hematology, 2007
- Decreased TCR ?-chain expression in T cells from patients with acquired aplastic anaemiaBritish Journal of Haematology, 2007
- High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal HaemoglobinuriaThrombosis and Haemostasis, 2005
- PROLONGATION OF RED‐CELL LIFE‐SPAN BY INCORPORATION OF DECAY‐ACCELERATING FACTOR (DAF) INTO RED CELLS OF PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH)British Journal of Haematology, 1989
- Deficiency of the Complement Regulatory Protein, Decay-Accelerating Factor, on Membranes of Granulocytes, Monocytes, and Platelets in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 1985